ArticleCancer2014

Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for front-line therapy of pleural mesothelioma and correlation of tumor response with serum mesothelin, megakaryocyte potentiating factor, and cancer antigen 125.

Raffit Hassan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.